Evogene Spotlights AI-Driven Drug Discovery at BIO Convention
Event summary
- Evogene will present its pharma division's achievements at the BIO International Convention in San Diego on June 23, 2026.
- Dr. Gabi Tarcic, Chief Development Officer, will deliver an oral presentation on AI-driven small-molecule discovery.
- ChemPass AI™ will be highlighted as a tool for collaborative drug discovery with pharma and biotech partners.
- Evogene's management will be available for one-on-one meetings during the conference.
The big picture
Evogene's presentation at the BIO International Convention underscores the growing importance of AI in drug discovery, a trend accelerating as pharma companies seek more efficient and cost-effective methods for developing new therapies. The company's focus on collaborative partnerships highlights the strategic shift towards leveraging external expertise and resources to drive innovation. Success in this area could position Evogene as a key player in the AI-driven pharmaceutical sector.
What we're watching
- Partnership Potential
- How Evogene's ChemPass AI™ will attract and sustain collaborations with pharmaceutical and biotech partners.
- Technological Validation
- Whether the presentation will demonstrate tangible breakthroughs in AI-driven small-molecule discovery.
- Market Differentiation
- The pace at which Evogene can differentiate itself in the competitive AI-driven drug discovery space.
Related topics